Source | Evidence on protein | Close homologs |
---|---|---|
Cuervo et al. | no | yes: 0 |
Hassani et al. | no | yes: 0 |
Forrest at al. (metacyclic) | no | yes: 0 |
Forrest at al. (procyclic) | no | yes: 0 |
Silverman et al. | no | yes: 0 |
Pissara et al. | no | yes: 0 |
Source | Evidence on protein | Close homologs |
---|---|---|
Pires et al. | no | yes: 0 |
Source | Evidence on protein | Close homologs |
---|---|---|
Silverman et al. | no | yes: 0 |
Source | Evidence on protein | Close homologs |
---|---|---|
Jamdhade et al. | no | yes: 0 |
Source | Evidence on protein | Close homologs |
---|---|---|
DeepLoc | ||
SignalP6 | no | yes: 0, no: 6 |
NetGPI | no | yes: 0, no: 6 |
Related structures:
AlphaFold database: A0A3Q8ICT3
Term | Name | Level | Count |
---|---|---|---|
GO:0003824 | catalytic activity | 1 | 1 |
GO:0016491 | oxidoreductase activity | 2 | 1 |
Leishmania | From | To | Domain/Motif | Score |
---|---|---|---|---|
CLV_NRD_NRD_1 | 234 | 236 | PF00675 | 0.544 |
CLV_PCSK_KEX2_1 | 234 | 236 | PF00082 | 0.544 |
CLV_PCSK_KEX2_1 | 99 | 101 | PF00082 | 0.470 |
CLV_PCSK_PC1ET2_1 | 99 | 101 | PF00082 | 0.470 |
CLV_PCSK_SKI1_1 | 138 | 142 | PF00082 | 0.466 |
CLV_PCSK_SKI1_1 | 28 | 32 | PF00082 | 0.551 |
CLV_PCSK_SKI1_1 | 313 | 317 | PF00082 | 0.479 |
CLV_PCSK_SKI1_1 | 376 | 380 | PF00082 | 0.496 |
CLV_Separin_Metazoa | 383 | 387 | PF03568 | 0.431 |
DEG_APCC_DBOX_1 | 233 | 241 | PF00400 | 0.692 |
DEG_APCC_DBOX_1 | 375 | 383 | PF00400 | 0.436 |
DEG_SPOP_SBC_1 | 243 | 247 | PF00917 | 0.619 |
DOC_CYCLIN_RxL_1 | 25 | 33 | PF00134 | 0.501 |
DOC_CYCLIN_yCln2_LP_2 | 226 | 232 | PF00134 | 0.550 |
DOC_CYCLIN_yCln2_LP_2 | 264 | 270 | PF00134 | 0.511 |
DOC_MAPK_gen_1 | 194 | 203 | PF00069 | 0.523 |
DOC_MAPK_MEF2A_6 | 194 | 203 | PF00069 | 0.523 |
DOC_PP1_RVXF_1 | 136 | 143 | PF00149 | 0.470 |
DOC_PP2B_LxvP_1 | 226 | 229 | PF13499 | 0.518 |
DOC_PP4_FxxP_1 | 116 | 119 | PF00568 | 0.707 |
DOC_SPAK_OSR1_1 | 196 | 200 | PF12202 | 0.522 |
DOC_USP7_MATH_1 | 181 | 185 | PF00917 | 0.604 |
DOC_USP7_MATH_1 | 243 | 247 | PF00917 | 0.711 |
DOC_USP7_UBL2_3 | 215 | 219 | PF12436 | 0.504 |
DOC_USP7_UBL2_3 | 363 | 367 | PF12436 | 0.504 |
LIG_14-3-3_CanoR_1 | 182 | 186 | PF00244 | 0.497 |
LIG_14-3-3_CanoR_1 | 296 | 302 | PF00244 | 0.566 |
LIG_APCC_ABBA_1 | 6 | 11 | PF00400 | 0.500 |
LIG_BIR_II_1 | 1 | 5 | PF00653 | 0.584 |
LIG_BIR_III_4 | 287 | 291 | PF00653 | 0.526 |
LIG_BIR_III_4 | 81 | 85 | PF00653 | 0.544 |
LIG_deltaCOP1_diTrp_1 | 78 | 85 | PF00928 | 0.562 |
LIG_FHA_1 | 155 | 161 | PF00498 | 0.564 |
LIG_FHA_1 | 31 | 37 | PF00498 | 0.539 |
LIG_FHA_1 | 364 | 370 | PF00498 | 0.552 |
LIG_FHA_2 | 175 | 181 | PF00498 | 0.499 |
LIG_FHA_2 | 200 | 206 | PF00498 | 0.409 |
LIG_FHA_2 | 257 | 263 | PF00498 | 0.443 |
LIG_FHA_2 | 378 | 384 | PF00498 | 0.405 |
LIG_Integrin_isoDGR_2 | 136 | 138 | PF01839 | 0.504 |
LIG_Integrin_RGD_1 | 21 | 23 | PF01839 | 0.579 |
LIG_Integrin_RGD_1 | 284 | 286 | PF01839 | 0.572 |
LIG_LIR_Apic_2 | 113 | 119 | PF02991 | 0.696 |
LIG_LYPXL_yS_3 | 121 | 124 | PF13949 | 0.472 |
LIG_REV1ctd_RIR_1 | 139 | 149 | PF16727 | 0.517 |
LIG_REV1ctd_RIR_1 | 209 | 216 | PF16727 | 0.524 |
LIG_SH2_CRK | 348 | 352 | PF00017 | 0.480 |
LIG_SH2_STAT3 | 230 | 233 | PF00017 | 0.549 |
LIG_SH2_STAT5 | 231 | 234 | PF00017 | 0.539 |
LIG_SH2_STAT5 | 278 | 281 | PF00017 | 0.400 |
LIG_SH2_STAT5 | 350 | 353 | PF00017 | 0.470 |
LIG_SH3_3 | 116 | 122 | PF00018 | 0.617 |
LIG_SH3_3 | 248 | 254 | PF00018 | 0.606 |
LIG_SH3_3 | 84 | 90 | PF00018 | 0.520 |
LIG_SUMO_SIM_anti_2 | 256 | 262 | PF11976 | 0.555 |
LIG_SUMO_SIM_anti_2 | 266 | 276 | PF11976 | 0.395 |
LIG_SUMO_SIM_anti_2 | 380 | 386 | PF11976 | 0.410 |
LIG_SUMO_SIM_par_1 | 256 | 262 | PF11976 | 0.555 |
LIG_TRAF2_1 | 177 | 180 | PF00917 | 0.634 |
LIG_UBA3_1 | 210 | 219 | PF00899 | 0.474 |
MOD_CK2_1 | 174 | 180 | PF00069 | 0.626 |
MOD_CK2_1 | 181 | 187 | PF00069 | 0.545 |
MOD_CK2_1 | 199 | 205 | PF00069 | 0.374 |
MOD_CK2_1 | 243 | 249 | PF00069 | 0.697 |
MOD_CK2_1 | 377 | 383 | PF00069 | 0.409 |
MOD_GlcNHglycan | 23 | 27 | PF01048 | 0.551 |
MOD_GlcNHglycan | 304 | 307 | PF01048 | 0.511 |
MOD_GlcNHglycan | 44 | 48 | PF01048 | 0.553 |
MOD_GSK3_1 | 101 | 108 | PF00069 | 0.548 |
MOD_GSK3_1 | 22 | 29 | PF00069 | 0.574 |
MOD_GSK3_1 | 238 | 245 | PF00069 | 0.653 |
MOD_N-GLC_1 | 243 | 248 | PF02516 | 0.603 |
MOD_NEK2_1 | 124 | 129 | PF00069 | 0.537 |
MOD_NEK2_1 | 13 | 18 | PF00069 | 0.476 |
MOD_NEK2_1 | 30 | 35 | PF00069 | 0.539 |
MOD_NEK2_1 | 43 | 48 | PF00069 | 0.350 |
MOD_NEK2_2 | 26 | 31 | PF00069 | 0.527 |
MOD_PKA_2 | 110 | 116 | PF00069 | 0.637 |
MOD_PKA_2 | 181 | 187 | PF00069 | 0.501 |
MOD_Plk_1 | 13 | 19 | PF00069 | 0.534 |
MOD_Plk_1 | 43 | 49 | PF00069 | 0.549 |
MOD_Plk_2-3 | 174 | 180 | PF00069 | 0.565 |
MOD_Plk_2-3 | 187 | 193 | PF00069 | 0.583 |
MOD_Plk_4 | 181 | 187 | PF00069 | 0.591 |
MOD_Plk_4 | 253 | 259 | PF00069 | 0.579 |
MOD_Plk_4 | 26 | 32 | PF00069 | 0.554 |
MOD_SUMO_rev_2 | 248 | 257 | PF00179 | 0.541 |
MOD_SUMO_rev_2 | 44 | 54 | PF00179 | 0.430 |
TRG_DiLeu_BaEn_1 | 266 | 271 | PF01217 | 0.513 |
TRG_DiLeu_BaEn_1 | 312 | 317 | PF01217 | 0.491 |
TRG_DiLeu_LyEn_5 | 159 | 164 | PF01217 | 0.537 |
TRG_ENDOCYTIC_2 | 121 | 124 | PF00928 | 0.472 |
TRG_ENDOCYTIC_2 | 348 | 351 | PF00928 | 0.495 |
Protein | Taxonomy | Sequence identity | Coverage |
---|---|---|---|
A0A3Q8IJF2 | Leishmania donovani | 100% | 100% |
A4H906 | Leishmania braziliensis | 76% | 100% |
A4HXD7 | Leishmania infantum | 99% | 100% |
E9AR32 | Leishmania mexicana (strain MHOM/GT/2001/U1103) | 93% | 100% |
N4WEA4 | Cochliobolus heterostrophus (strain C4 / ATCC 48331 / race T) | 30% | 82% |
Q4QED1 | Leishmania major | 94% | 100% |